Skip to main content

Advertisement

SpringerLink
Log in

Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

We report on a chronic hepatitis C patient who developed hepatocellular carcinoma (HCC) 18 years after achieving a sustained virological response (SVR) to interferon therapy. We also review other reports of patients who developed HCC a long time after interferon therapy. The patient was a 67-year-old man with chronic hepatitis C who achieved an SVR to interferon therapy at the age of 49 years in 1992. Eighteen years later, however, a tumor measuring 19 mm in diameter in segment 7 of the liver was found by abdominal ultrasound. The tumor had a typical HCC enhancement pattern by dynamic computed tomography. A moderately to poorly differentiated HCC was confirmed by fine-needle aspiration biopsy. Fibrosis and inflammation in the liver parenchyma improved pathologically from F3A2 to F2A1 according to the New Inuyama Classification. Liver steatosis remained after achieving an SVR and the serum alanine aminotransferase level was persistently slightly elevated. The HCC was treated by transcatheter arterial chemoembolization combined with radiofrequency ablation. Patients with chronic hepatitis C who have achieved an SVR to interferon therapy, and those who have risk factors for the development of HCC, such as being male, of advanced age (<50 years is rare), or with progressive liver fibrosis and steatosis as a hepatic manifestation of metabolic syndrome, should undergo careful long-term follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–65.

    Article  PubMed  CAS  Google Scholar 

  2. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483–91.

    Article  PubMed  CAS  Google Scholar 

  3. Ikeda M, Kinoyama S, Niiyama G, et al. A case of chronic hepatitis C developing from a small hepatocellular carcinoma 18 months after elimination of serum hepatitis C virus RNA by interferon therapy. Acta Hepatol Jpn. 1995;36:485–90.

    Article  Google Scholar 

  4. Sugiura N, Sakai Y, Ebara M, et al. Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: clinical study of 26 cases. J Gastroenterol Hepatol. 1996;11:535–9.

    Article  PubMed  CAS  Google Scholar 

  5. Tamori A, Kuroki T, Nishiguchi S, et al. Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Hepatogastroenterology. 1996;43:1079–83.

    PubMed  CAS  Google Scholar 

  6. Hirashima N, Mizokami M, Orito E, et al. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon alpha. J Gastroenterol Hepatol. 1996;11:955–8.

    PubMed  CAS  Google Scholar 

  7. Miyano S, Togashi H, Shinzawa H, et al. Case report: occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol. 1999;14:928–30.

    Article  PubMed  CAS  Google Scholar 

  8. Inoue M, Ohhira M, Ohtake T, et al. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy. Hepatogastroenterology. 1999;46:2554–60.

    PubMed  CAS  Google Scholar 

  9. Yamaguchi K, Omagari K, Kinoshita H, et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to interferon alpha. J Clin Gastroenterol. 1999;29:207–9.

    Article  PubMed  CAS  Google Scholar 

  10. Mori K, Haruna Y. Hepatocellular carcinoma appearing after eight-year and six-month-long sustained viral response by interferon therapy for chronic hepatitis C. Acta Hepatol Jpn. 2003;44:296–300.

    Article  Google Scholar 

  11. Ito Y, Yamamoto N, Nakata R, et al. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol. 2005;11:7218–21.

    PubMed  Google Scholar 

  12. Kawano Y, Egami K, Sasajima K, et al. A hepatocellular carcinoma developed following 12 years from sustained virologic response to interferon therapy in a patient with hepatitis C. Acta Hepatol Jpn. 2007;48:48–56.

    Article  Google Scholar 

  13. Yagura M, Tanaka A, Kamitsukasa H. A case of hepatocellular carcinoma who cleared hepatitis C virus with interferon therapy 13 years ago. Acta Hepatol Jpn. 2009;50:238–43.

    Article  Google Scholar 

  14. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–402.

    Article  PubMed  CAS  Google Scholar 

  15. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–30.

    Article  PubMed  CAS  Google Scholar 

  16. Suganami F, Tomiyama Y, Ohmoto K, et al. Hepatocellular carcinoma occurring after 11 year-long sustained viral response to interferon therapy for chronic hepatitis C. J Jpn Soc Gastroenterol. 2007;104:809–14.

    Google Scholar 

  17. Hanaoka J, Shimada M, Ikegami T, et al. A case of surgical treatment for hepatocellular carcinoma that developed in a chronic hepatitis C patient who had shown sustained virological response to interferon 11 years before. Acta Hepatol Jpn. 2008;49:248–54.

    Article  Google Scholar 

  18. Tsumura T, Takaki S, Aikata H, et al. A case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after diminution of HCV-RNA. J Jpn Soc Gastroenterol. 2009;106:674–83.

    Google Scholar 

  19. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–22.

    Article  PubMed  CAS  Google Scholar 

  20. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463–71.

    Article  PubMed  Google Scholar 

  21. Ertle J, Dechêne A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436–43.

    Article  PubMed  CAS  Google Scholar 

  22. Shao RX, Hoshida Y, Otsuka M, et al. Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. World J Gastroenterol. 2005;11:1995–9.

    PubMed  CAS  Google Scholar 

  23. Tomimaru Y, Sasaki Y, Yamada T, et al. Fibrosis in non-cancerous tissue is the unique prognostic factor for primary hepatocellular carcinoma without hepatitis B or C viral infection. World J Surg. 2006;30:1729–35.

    Article  PubMed  Google Scholar 

  24. Swain M, Heathcote EJ, Lai MY, et al. Long-lasting sustained virological response in chronic hepatitis C patients previously treated with 40 kDa peginterferon alpha 2a. Hepatology. 2001;34:330A.

    Article  Google Scholar 

  25. McHutchison JG, Davis GL, Esteban-Mur R, et al. Durability of sustained virologic response in patients with chronic hepatitis C after treated with interferon alpha 2b alone or in combination with ribavirin. Hepatology. 2001;34:244A.

    Google Scholar 

  26. McHutchison JG, Poynard T, Esteban-Mur R, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002;35:688–93.

    Article  PubMed  CAS  Google Scholar 

  27. Hige S. Measurement of strand-specific hepatic HCV-RNA quantities of patients with hepatitis C virus infection. Nippon Rinsho. 2004;62:417–21.

    PubMed  Google Scholar 

  28. Moriya K, Fujiie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–7.

    Article  PubMed  CAS  Google Scholar 

  29. Tamori A, Nishiguchi S, Shiomi S, et al. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol. 2005;100:1748–53.

    Article  PubMed  CAS  Google Scholar 

  30. Paterlini-Brechot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene. 2003;22:3911–6.

    Article  PubMed  CAS  Google Scholar 

  31. Elmore LW, Hancock AR, Chang SF, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA. 1997;94:14707–12.

    Article  PubMed  CAS  Google Scholar 

  32. Sanefuji K, Kayashima H, Iguchi T, et al. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C. J Surg Oncol. 2009;99:32–7.

    Article  PubMed  CAS  Google Scholar 

  33. Hayashi T, Tamori A, Nishikawa M, et al. Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection. Liver Int. 2009;29:126–32.

    Article  PubMed  CAS  Google Scholar 

  34. Majima Y. Growth rate of hepatocellular carcinoma by ultrasonography and its clinical significance. Acta Hepatol Jpn. 1984;25:754–65.

    Article  Google Scholar 

  35. Uenishi T, Kubo S, Hirohashi K, et al. Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2002;24:404–12.

    Article  PubMed  CAS  Google Scholar 

  36. Ikeda K, Kobayashi M, Saitoh S, et al. Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus-RNA by interferon therapy. A closed cohort study using matched control patients. Oncology. 2003;65:204–10.

    Article  PubMed  CAS  Google Scholar 

  37. Nagaoki Y, Aikata H, Miyaki D, et al. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol. 2011;46:799–808.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank the nurses and our colleagues in the Department of Gastroenterology and on the Gastroenterology Ward at Kobe University Hospital for their cooperation with our report.

Conflict of interest

We declare that we have no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

    Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Masaru Yoshida & Takeshi Azuma

  2. Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan

    Yoshihiko Yano

  3. Division of Diagnostic Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan

    Yukiko Morinaga & Tomoo Itoh

  4. Division of Metabolomics Research, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

    Masaru Yoshida

Authors
  1. Masaya Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasushi Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihiko Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akira Miki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yukiko Morinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoo Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masaru Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Azuma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saito, M., Seo, Y., Yano, Y. et al. Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review. Clin J Gastroenterol 5, 119–126 (2012). https://doi.org/10.1007/s12328-012-0284-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-012-0284-7

Keywords

Search

Navigation